PKD Clinical and Translational Core Study
NCT01873235
Recruiting
Advances in our understanding of the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD) have opened up possibilities of new therapies to prevent disease progression. High quality clinical investigations in patients with ADPKD, however, pose significant challenges to investigators including limited access to patients with ADPKD,insufficient guidance by experienced investigators and lack of resources to conduct these studies. The Polycystic Kidney Disease Research Clinical and T... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2024
Locations: University of Maryland School of Medicine General Clinical Research Center, Baltimore, Maryland
Conditions: Polycystic Kidney Disease
Register for Updates
Defining the Basis of Fibromuscular Dysplasia (FMD)
NCT01967511
Recruiting
The purpose of this study has evolved and expanded since its inception. Originally the intent was to establish the functional, molecular and genetic profile of fibroblasts from Fibromuscular Dysplasia (FMD) patients as compared to carefully matched control subjects. While this remains among the objectives, the study has been expanded to undertake a fully powered cross-tissue systems genetics analysis of FMD, and now also the related arteriopathies spontaneous coronary artery dissection (SCAD) an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Fibromuscular Dysplasia, Spontaneous Coronary Artery Dissection, Cervical Artery Dissection
Register for Updates
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
NCT02559778
Recruiting
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Gender:
ALL
Ages:
22 years and below
Trial Updated:
08/21/2024
Locations: University of Alabama, Children's of Alabama, Birmingham, Alabama +25 locations
Conditions: Neuroblastoma
Register for Updates
Sex Differences in the Response to Abstinence From Alcohol.
NCT03827460
Recruiting
In laboratory animals, repeated cycles of abstinence from and return to alcohol drinking can lead to changes in alcohol intake. In a study of the effect of abstinence on drinking in humans, the investigators found evidence that abstinence affects drinking differently in women compared to men. In the present study, the investigators propose to study how men and women respond to abstinence, and whether this information can be used to improve intervention and prevention strategies.
Gender:
ALL
Ages:
Between 21 years and 35 years
Trial Updated:
08/21/2024
Locations: University Hospital, Indianapolis, Indiana
Conditions: Alcohol Use Disorder
Register for Updates
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457
Recruiting
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Ste... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/21/2024
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +841 locations
Conditions: Multiple Myeloma
Register for Updates
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
NCT04598009
Recruiting
This phase II trial studies how well binimetinib and imatinib work in treating patients with stage III-IV KIT-mutant melanoma that cannot be removed by surgery (unresectable). Binimetinib and imatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and imatinib may help treat patients with KIT-mutant melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2024
Locations: UC San Diego Moores Cancer Center, La Jolla, California +1 locations
Conditions: Melanoma Stage III, Melanoma Stage IV
Register for Updates
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
NCT04857684
Recruiting
This study is evaluating the safety and tolerability of neoadjuvant stereotactic body radiation therapy (SBRT) with atezolizumab and bevacizumab for treating resectable hepatocellular carcinoma. This study involves the following study interventions: * Atezolizumab * Bevacizumab * Stereotactic Beam Radiation Therapy (SBRT) * Surgery
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
Register for Updates
Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections
NCT05217537
Recruiting
The purpose of this study is to evaluate the pharmacokinetics of a single dose of intravenous or oral omadacycline in children and adolescents with suspected or confirmed bacterial infections.
Gender:
ALL
Ages:
Between 8 years and 17 years
Trial Updated:
08/21/2024
Locations: Site 109, Little Rock, Arkansas +8 locations
Conditions: Bacterial Infections
Register for Updates
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
NCT05255354
Recruiting
In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy patients. The project detailed in this protocol will utilize the clonoSEQ platform as specific quantification of residual DLBCL/FL/MCL and correlate its results with radiologic assessment of disease and clinical outcomes. Invesitgators predict there will be a strong correlati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2024
Locations: Stanford Cancer Center, Palo Alto, California
Conditions: Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma
Register for Updates
Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism
NCT05264623
Recruiting
This will be a multicenter, prospective, open label, non-randomized, single arm 12 month study, evaluating the safety and effectiveness of the TECHNOLAS TENEO 317 Model 2 (Software version "1.28 US") excimer laser when used in LASIK surgery to treat hyperopia with or without hyperopic astigmatism. Both eyes of a subject may be enrolled so long as both eyes meet all inclusion/exclusion requirements. Analysis of the primary effectiveness endpoint will be completed at refractive stability.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
08/21/2024
Locations: Site 113, Newport Beach, California +11 locations
Conditions: Hyperopia
Register for Updates
Improving Comprehensive Care of Cancer Patients
NCT05323409
Recruiting
Cancer survivors have unique healthcare needs, including managing serious late effects, ongoing surveillance, lifestyle modifications to reduce second cancer risk, and psychosocial support. Nearly 70% of survivors have at least one comorbid chronic condition in addition to cancer, which complicates the delivery of quality cancer care. Medically underserved patients, who bear the highest burden of multiple chronic conditions, are at increased risk for poor outcomes during and after cancer treatme... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2024
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Breast Cancer, Gastrointestinal Cancer, Hematologic Cancer
Register for Updates
The Effect of Sleep Loss on Emotion Regulation
NCT05393830
Recruiting
The study is designed to investigate the impact of three nights of sleep restricted to 4 hours per night, on the processing and regulation of emotional information compared to Insomnia Disorder and control. The investigators will address and attempt to answer two questions. (i) How do three nights of reduced sleep or a diagnosis of Insomnia Disorder affect the processing and regulation of emotional information compared to typical, undisturbed sleep? (ii) What overlapping and distinct neural mec... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
08/21/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Sleep, Insomnia, Sleep Deprivation
Register for Updates